Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Hematology: Other hemapoietic

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis

To evaluate the efficacy of NEOD001 plus SOC vs. placebo + SOC when administered intravenously in subjects with AL amyloidosis by assessing time to all-cause mortality or cardiac hospitalization.

Status: Accepting New Patients
Principal Investigator: Seema Singhal

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies

The purpose of this research is to evaluate the safety and tolerability of the investigational drug, INCB053914, and to select the doses that will be studied further in people with advanced cancers or diseases where cells grow too much.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

The purpose of this study is to identify and test the highest dose of AG-120 that can be given safely. We want to find out what effects, good or bad, it has on patients and their disease.

Status: Accepting New Patients
Principal Investigator: Jessica Altman

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinase A, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelofibrosis)

The main purpose of the study is to determine how safe and tolerable the study drug, Alisertib, is in patients with AMKL and in patients with MF.

Status: Accepting New Patients
Principal Investigator: Brady Stein

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Hematologic Malignancies with an IDH1 and/or IDH2 Mutation

This purpose of this study is to find out how safe and tolerable the study drug AG-881 is in patients with hematological cancers which does not respond to standard treatment. Patients diagnosed with the following types of blood cancers - Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) Myeloproliferative Neoplasm (MPN) or Angioimmunoblastic T-cell Lymphoma (AITL) may qualify for the study. The main purpose of the study is to identify and test the highest dose of the study drug (AG-881) that can be given safely to patients. This drug is designed to target two proteins known as Isocitrate Dehydrogenase (IDH1 and IDH2), which have been discovered to be critical for cancer cell growth by supporting its enhanced metabolic activity. Researchers have discovered that many types of blood cancers have mutations in this protein that causes it to become overactive. The study will mainly answer the following questions: 1) the maximum dose that can be given to the patient with minimal side effects; 2) the amount of the study drug that gets into the blood stream at different time points and what it does to the body after being taken orally.

Status: Accepting New Patients
Principal Investigator: Jessica Altman

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway.

Status: Accepting New Patients
Principal Investigator: Young Chae

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

There are 2 parts to this study (phase II and phase III). The part of the study in which a participant is enrolled depends on the timing of starting in the study. The purpose of the phase II part of the study is to treat the cancer that has spread to a participant's spine, and is causing pain, with image-guided radiosurgery/SBRT. The purpose of phase III is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.

Status: Accepting New Patients
Principal Investigator: John Kalapurakal

last updated: Tue - July 26, 2016 - 02:40 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.